In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osiris Therapeutics Inc.

http://www.osiris.com

Latest From Osiris Therapeutics Inc.

Deal Time! Smith & Nephew Snaps Up Leaf Healthcare For Wound Portfolio

Smith & Nephew is continuing its acquisition spree by picking up Leaf Healthcare, the developer of a pressure injury prevention device, to bolster its advanced wound management portfolio.

M & A Commercial

Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.

Regenerative Medicine Research & Development

Market Intel: Orthobiologics Market Well-Positioned For Innovative Reconstruction

Global sales of orthobiologics for musculoskeletal soft tissue replacement and regeneration are predicted to hit $1.4bn by 2021, driven largely by rising numbers of sports injuries requiring treatment, but also by a higher prevalence of osteoarthritis and a need for innovative treatments for musculoskeletal repair. This article offers an in-depth look at the orthobiologics market landscape for cartilage, meniscus and ligament/tendon replacement and regeneration, as well as insight from an orthopedic surgeon. It also analyzes key players in these markets and highlights emerging trends and the greatest barriers for wider adoption of products.

Orthopedics Cellular & Genetic

Finance Watch: Canaan Closes New VC Fund; CARB-X Backs More Antibiotics

Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Osiris Therapeutics Inc.
  • Senior Management
  • Samson Tom, Pres. & CEO
    Joel Rogers, CFO
    Alla Danilkovitch, PhD, CSO
    Jason Keefer, Chief Commercial Officer
  • Contact Info
  • Osiris Therapeutics Inc.
    Phone: (443) 545-1819
    7015 Albert Einstein Dr.
    Columbia, MD 21046-1707
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register